查詢結果分析
相關文獻
- The Efficacy of Nebulized Beta-2 Agonist Bronchodilator Therapy in the Treatment of Acute Bronchiolitis
- 超長效的支氣管擴張劑
- Inflammatory, Immunological and Clinical Comparisons of Short- and Long-acting Bronchodilators in Mild and Moderate Bronchial Asthma Patients
- 吸入性支氣管擴張劑於細支氣管炎所扮演的角色
- Theophylline中毒及處置
- 兒童氣喘病治療藥物的新發展
- 頑固性氣喘(Difficult Asthma)
- Formoterol (Oxis Turbuhaler[feb9])--兼具速效與長效的支氣管擴張劑
- 慢性阻塞性肺疾支氣管擴張劑治療
- 氣霧化支氣管擴張劑之過去現在與未來
頁籤選單縮合
題 名 | The Efficacy of Nebulized Beta-2 Agonist Bronchodilator Therapy in the Treatment of Acute Bronchiolitis=噴霧式支氣管擴張劑在治療急性細支氣管炎之評估 |
---|---|
作 者 | 鍾全生; 黃永豐; 劉秋聯; 劉保寧; 蔡東烜; 陳英堯; 謝凱生; | 書刊名 | 慈濟醫學 |
卷 期 | 10:2 1998.06[民87.06] |
頁 次 | 頁95-101 |
分類號 | 418.263 |
關鍵詞 | 支氣管擴張劑; 乙二型交感神經支氣管擴張劑; 噴霧式療法; 急性細支氣管炎; Beta-2 agonist bronchodilator; Terbutaline; Nebulizer therapy; Acute bronchiolitis; |
語 文 | 英文(English) |
中文摘要 | 急性細支氣管炎為嬰幼兒常見之下呼吸道疾病,引起急性下呼吸道阻塞,常造成 急性呼吸困難之症狀。為評估經由面罩噴霧式投與乙二型交感神經支氣管擴張劑(Terbutaline) 之療效,在於支氣管收縮急性細支氣管炎病人所扮演的角色;我們收集了38位病人,分成 2組:第一組為治療組,第二組為安慰劑組。我們發現全部病人在呼吸速率、心跳、使用副 肌肉分數(accessory muscle score)、哮鳴分數(wheeze score)、血氧飽和及呼氣末二氧化碳濃度 變化,均有改善的現象。尤其在第二天症狀改善特別明顯。但二組之間在第二天的治療效果 並無統計統學上意義。此實驗指出臨床常用於急性細支管炎的乙二型交感神經支氣管擴張劑 的噴霧療法並無臨床上的明顯意義。所以治療上還需傳統保守療法,如給予濕冷氧氣的環境 以減緩低血氧及呼吸過速所造成之不可見水喪失。因此,在嬰幼兒急性細支氣管炎時,給予 乙型交感神經擴張劑並非必要之處理。 |
英文摘要 | Acute bronchiolitis is a common lower respiratory tract infections in infants and toddlers less than 3 years old. In order to evaluate the effectiveness of the nebulized beta-2 agonist bronchodilator, Terbutaline, in the treatment of acute bronchiolitis, we collected thirty-eight young children suffering from acute bronchiolitis and divided them into a treatment group and a placebo group. Clinical data on respiratory rate, heart rate, accessory muscles motor score, wheezing score and the oxygen saturation and end-tidal carbon dioxide concentration were recorded in all patients before and after treatment. Both groups improved after treatment, especially on the second day and without obvious side effects. We concluded that the nebulized beta-2 agonist bronchodilator, Terbutaline, does not produce a clinical benefit superior to placebo in the treatment of bronchiolitis. |
本系統中英文摘要資訊取自各篇刊載內容。